Toledo Community Hospital Oncology Program (TCHOP) seeks funding to continue its ongoing Community Clinical Oncology Program to provide the most advanced knowledge and technology currently achieved through cancer prevention and treatment trials to both urban and rural communities throughout its catchment area. Since receiving original funding in 1982, the Toledo CCOP has grown to include 17 components and institutions within the consortium. The catchment area has expanded to include Northwest and Northeast Ohio, Southeast Michigan and Eastern Virginia. The Toledo CCOP's strengths are: 25 years of positively contributing to National Cancer Institute's success in community-based research;a strong record of accrual to both treatment and prevention/control trials;experienced and effective organizational management;dedicated physician participation;and leadership in scientific and committee activities with the cooperative groups. TCCOP has in place adequate plans and support personnel to follow-up participants enrolled in large prevention trials. Finally, TCCOP's improved data management and communication infrastructure will support increased accrual while maintaining appropriate standards in an effective efficient manner that assures quality and TCCOP's ability to meet requirements of the Research Base and Federal entities. With funding through the National Cancer Institute Community Clinical Oncology Program (U10), TCCOP will persist in contributing to the discovery of treatment options for people who have been devastated by a cancer diagnosis.
Clinical research trials are necessary to advance and improve treatment outcomes of patients diagnosed with cancer. The growing body of knowledge from previous clinical cancer research trials has promoted healthy lifestyles to prevent or postpone the onset of cancer. However, many questions remain unanswered which require community participation in cancer research.
|Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55|
|Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade â‰¥ 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:|
|Park, Haeseong; Qin, Rui; Smith, Thomas J et al. (2015) North Central Cancer Treatment Group N10C2 (Alliance): a double-blind placebo-controlled study of magnesium supplements to reduce menopausal hot flashes. Menopause 22:627-32|
|Liu, Heshan; Tan, Angelina D; Qin, Rui et al. (2015) Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients. SOJ Anesthesiol Pain Manag 2:|
|Dueck, A C; Singh, J; Atherton, P et al. (2015) Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance). Osteoporos Int 26:1971-7|
|Rule, William G; Foster, Nathan R; Meyers, Jeffrey P et al. (2015) Prophylactic cranial irradiation in elderly patients with small cell lung cancer: findings from a North Central Cancer Treatment Group pooled analysis. J Geriatr Oncol 6:119-26|
|Wagner-Johnston, Nina D; Sloan, Jeff A; Liu, Heshan et al. (2015) 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial. Cancer 121:2537-43|
|Schild, Michael H; Schild, Steven E; Wong, William W et al. (2014) Early Outcome of Prostate Intensity Modulated Radiation Therapy (IMRT) Incorporating a Simultaneous Intra-Prostatic MRI Directed Boost. OMICS J Radiol 3:|
|Singh, Jasvinder A; Satele, Daniel; Pattabasavaiah, Suneetha et al. (2014) Normative data and clinically significant effect sizes for single-item numerical linear analogue self-assessment (LASA) scales. Health Qual Life Outcomes 12:187|
|Van Loon, Katherine; Espinoza, Anne M; Fogelman, David R et al. (2014) Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas 43:343-9|
Showing the most recent 10 out of 125 publications